Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review

Murton, Molly, Drane, Emma, Jarrett, James, Cornely, Oliver A. ORCID: 0000-0001-9599-3137 and Soriano, Alex ORCID: 0000-0002-9374-0811 . Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review. Infection. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-0973

Full text not available from this repository.

DOI:10.1007/s15010-022-01930-8

Abstract

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has been a global health emergency since December 2019, leading to millions of deaths worldwide and placing significant pressures, including economic burden, on individual patients and healthcare systems. As of February 2022, remdesivir is the only US Food and Drug Administration (FDA)-approved treatment for severe COVID-19. This systematic literature review (SLR) aimed to summarise economic evaluations, and cost and resource use (CRU) evidence related to remdesivir during the COVID-19 pandemic. Methods Searches of MEDLINE, Embase the International Health Technology Assessment (HTA) database, reference lists, congresses and grey literature were performed in May 2021. Articles were reviewed for relevance against pre-specified criteria by two independent reviewers and study quality was assessed using published checklists. Results Eight studies reported resource use and five reported costs related to remdesivir. Over time, the prescription rate of remdesivir increased and time from disease onset to remdesivir initiation decreased. Remdesivir was associated with a 6% to 21.3% decrease in bed occupancy. Cost estimates for remdesivir ranged widely, from $10 to $780 for a 10-day course. In three out of four included economic evaluations, remdesivir treatment scenarios were cost-effective, ranging from similar to 8 to similar to 23% of the willingness-to-pay threshold for the respective country. Conclusions Economic evidence relating to remdesivir should be interpreted with consideration of the broader clinical context, including patients' characteristics and the timing of its administration. Nonetheless, remdesivir remains an important option for physicians in aiming to provide optimal care and relieve pressure on healthcare systems through shifting phases of the pandemic.

Item Type:

Journal Article

Creators:

Creators	Email	ORCID	ORCID Put Code
Murton, Molly	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Drane, Emma	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Jarrett, James	UNSPECIFIED	UNSPECIFIED	UNSPECIFIED
Cornely, Oliver A.	UNSPECIFIED	orcid.org/0000-0001-9599-3137	UNSPECIFIED
Soriano, Alex	UNSPECIFIED	orcid.org/0000-0002-9374-0811	UNSPECIFIED